Nanomerics on ice after founders get large grant from Wellcome Trust

We recently caught up with Andreas Schätzlein of the University of London. In describing his progress in developing a micelluar drug delivery technology and a dendrimer-based gene delivery vector, mention of his company Nanomerics (see the LRJ Nov 6 2006) was curiously absent. It turns out that Andr...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email Thank you!

Related Research

Nkarta Therapeutics receives clearance to start Phase I clinical trials for its CAR-NK cell therapy to treat B-cell malignancies

News Commentary | May 05, 2021

Chimeric antigen receptor T cell (CAR‑T) therapy is already clinically available, with five FDA‑approved therapies for cancers like leukemia, lymphoma, and multiple myeloma. Now, Nkarta, a clinical‑stage biotech company, is developing another version – a CAR‑natural killer (CAR‑NK) cell therapy. The... Not part of subscription

New insights about human immune response to COVID-19 have implications for vaccine design against new variants

News Commentary | May 07, 2021

Multiple new and emerging COVID‑19 variants with higher transmission rates have thrown into question the continued efficacy of existing vaccines across these newer strains. Previous research has focused on the receptor‑binding domain (RBD) given its importance in attaching to and infecting human ... To read more, click here.

Google-backed Calico and AbbVie announce second extension of a long-standing partnership to tackle aging-related diseases

News Commentary | July 30, 2021

Google‑backed Calico and pharma giant AbbVie are doubling down on tackling aging‑related diseases with this second partnership extension. Twenty early‑stage programs have been developed across oncology and neurodegeneration, with the lead oncology target, which acts at multiple steps in the cancer ... Not part of subscription